Clinical trials
Phase 2/3 Breast Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2008 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Terminated | 6 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Withdrawn | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 3 |
| Bristol-Myers Squibb | 1 |
| Celgene | 1 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 1 |
| Hoffmann-La Roche | 1 |
| Immutep S.A.S. | 1 |
| Koning Corporation | 1 |
| Medstar Health Research Institute | 1 |
| Merrimack Pharmaceuticals | 1 |
| NRG Oncology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 24 |
| Lung Neoplasms | 3 |
| Breast Carcinoma In Situ | 2 |
| Colorectal Neoplasms | 2 |
| Sarcoma | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Carcinoma, Intraductal, Noninfiltrating | 1 |
| Fatigue | 1 |
| Head and Neck Neoplasms | 1 |
| Hereditary Sensory and Autonomic Neuropathies | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.